GlassScriptPhysician profile
Sandra Blessing Okengwu
NPI 1225711047
$789.19
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $263.17 | 2024 | Austedo Xr, Uzedy |
| Abbvie INC. | $136.79 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $99.89 | 2024 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.21 | 2024 | Caplyta |
| Lundbeck LLC | $58.03 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $54.99 | 2024 | Cobenfy |
| Axsome Therapeutics, INC. | $27.59 | 2024 | Auvelity |
| Noven Therapeutics, LLC | $17.23 | 2024 | Xelstrym, Secuado |
| Janssen Pharmaceuticals, INC | $16.93 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Okengwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.